**ILSI Health and Environmental Sciences Institute (HESI)** 

### **Cardiac Safety Technical Committee**

## A Resource for Improving Cardiovascular Safety Through Collaboration

HESI Annual Meeting May 2010

www.hesiglobal.org



T

н



### **Session Overview**

Introduction you are here Dusty Sarazan DVM, Ph.D.(DSI) Functional CV Safety Evaluation ✤Dusty Sarazan DVM, Ph.D. (DSI) Cardiac Biomarkers Eric Schultze, DVM, Ph.D. (Lilly) ProArrhythmia Model Evaluation ✤ John Koerner, Ph.D. (FDA)

### **CV** Issues...How Real is the Problem?

Phase	Nonclinical	Phase I	Phase 1-III	Phase III/ Marketing	Marketing	Marketing
Information	Causes of attrition	Serious ADRs	Causes of attrition	ADRs on label	Serious ADRs	Withdrawal from sale
Source	Car (2006)	Sibille et al. (1998)	Olson et al. (2000)	BioPrint® (2006)	Budnitz et al. (2006)	Stevens & Baker (2008)
Sample size	88 CDs stopped	1,015 subjects	82 CDs stopped	1,138 drugs	21,298 patients	47 drugs
Cardiovascular	27%	9%	21%	36%	15%	45%
Hepatotoxicity	8%	7%	21%	13%	0%	32%
Haematology/BM	7%	2%	4%	16%	10%	9%
Nervous system	14%	28%	21%	67%	39%	2%
Immunotox; photosensitivity	7%	16%	11%	25%	34%	2%
Gastrointestinal	3%	23%	5%	67%	14%	2%
Reprotox	13%	0%	1%	10%	0%	2%
Musculoskeletal	4%	0%	1%	28%	3%	2%
Respiratory	2%	0%	0%	32%	8%	2%
Renal	2%	0%	9%	19%	2%	0%
Genetic tox	5%	0%	0%	0%	0%	0%
Carcinogenicity	3%	0%	0%	1%	0%	0%
Other	0%	0%	4%	16%	2%	2%
Redfern WS et al. SOT 2010 Poster 1081 Tue 1 pm         0%         1-9%         10-19%         >20%						20%

# Cardiac Safety Committee Mission

- To develop and disseminate improved data, approaches, and resources for the evaluation of preclinical and clinical cardiovascular toxicity.
- Bring preclinical scientists and clinicians together to address issues of contemporary concern relative to clinical cardiovascular safety.

# **Quick History**

- July 2008
  - Committee formation approved by HESI Board of Trustees
- January 2009
  - Committee officially initiated integrates pre-existing ProArrhythmia Models Project Committee and Cardiac Biomarkers Working Group
  - First Committee meeting held
- June 2009
  - Committee organized workshop (June 2-4, 2009) on Structural and Functional Approaches to Cardiovascular Safety Evaluation held in Washington, DC
- July 2009
  - New working groups on Functional & Predictive Cardiovascular Safety Evaluation formulated as follow-up to workshop.
- August 2009 Present
  - Committee provides structure and oversight of:
    - Proarrhythmia Models Working Group
    - Cardiac Biomarkers Working Group
    - Predictive Cardiovascular Safety Working Group
    - Functional Cardiovascular Safety Working Group

# Advisory Team

Advisory Team of Senior Scientists Established to Provide Input on Overall Program Direction and Impacts

- Dr. Norman Stockbridge, US FDA (Dir. FDA CardioRenal)
- Dr. Jan Regnstroem, European Medicines Agency (clinician)
- Dr. Eugene Herman, US FDA
- Dr. Eric Schultze, Lilly
- Dr. Jean-Pierre Valentin, AstraZeneca
- Dr. Kendall Wallace, U. of Minnesota
- Dr. Brian Berridge, GlaxoSmithKline
- Dr. Dusty Sarazan, Data Sciences International
- Dr. John Koerner, FDA

Staff: Syril D. Pettit, MEM, HESI Associate Director

## AN ACTIVE 16 MONTHS FOR ALL WORK GROUPS

Journal of Pharmacological and Toxicological Methods 60 (2009) 45-50





### Original article

A HESI consortium approach to assess the human predictive value of non-clinical repolarization assays

Elena S. Trepakova<sup>4,\*</sup>, John Koerner<sup>b,1</sup>, Syril D. Pettit<sup>c,2</sup>, and Jean-Pierre Valentin<sup>d,3</sup>

on behalf of the HESI Pro-Arrhythmia Committee members

<sup>4</sup> Mercic Research Laboratories, 770 Summericown Rile, 10 Eax 4, WR81-220, West Point, PA 19486, USA.
<sup>b</sup> Division of Cardiovascular and Renal Products, Center of Drug Evaluation and Research, US, Rood and Drug Administration, 10903 New Hampshire Avenue, WO-22, Suite 4178,

Series Spring, MD 2018th-00020, USA Science Spring, MD 2018th-00020, USA Science Rel Courseack, Health and Emirrorental Sciences Institute, 1156 15th Street, NW, 2nd floor, Woshington, DC 20005, USA AstroDerece ABO Materies Previx Sofery Assessment UK, Moreside, Atlenter, Park, Macchellell, Cheshine, SK10 4TG: United Kingdom

ABSTRACT

	sle hústory:
	rived 12 March 2009
Acc	epted 22 April 2009
Key	show
Ani	mai models
Car	tiac repolarization
Car	flac safety
ILS!	THEST
Pito	Arrhythmia Models Project Committe
OT	
OT	

Derg-induced wentikultar arabytimnia and Torsader, de Pointes remain a serious public health insues in Dorg-induced wentikultar arabytimnia and Torsader, de Pointes remain a serious public health insues in biotistic (ESD)-in-leafth and Eurisonmental Selences Institute (1985), a consortium involving representatives from pharmacentical comparies, regulatory agencies, and ophoton landers from the scientific and medica more clinical republication and the selection of the select

© 2009 Elsevier Inc. All rights reserved

1. Introduction

It is recognised that a subset of drug-induced sudden deaths is It is recognised that a subset of drug-induced audion deaths is for the subset of the subset of the subset of the subset of the formades de Pointeen (drug). The subset of the subset of the issue is that the most common primary event understanding of this issue is that the most common primary event understanding of the issue is that the most common primary event understanding of the issue is that the most common primary event understanding of the issue is that the most common primary event understanding of the plays a key role in repolarization of the cardiac action potential (dru review, set Tamango, 2000), inhibition of this current can prolong the

Althornoisine: EC, Elaboracidingame, PD, Food and Drug administration PTH First Time In Nume, IGE, Sold Laboracity Pacters Mark, Naman, Alber 4 go.go related gene, HES, Hoath and Environmental Sciences Institute (24), International Sold Laboracity (24), International Control (24), International Sold Laboracity (24), International Control (24), International Sold Laboracity (24), International Control (24), International Control (24), International Control (24), International Sold Laboracity (24), International Control (25), International International Laboracity (24), International Control (25), International International Control (25), International Control (25), International Environment (24), International Control (25), International Control (25), International Environment (25), International Control (25), International Control (25), International Internatio

Wids his gov (J. Koerner), spect & Olislorg (S.D. Pettit) als ndis@astrazoneca.com (J.-P. Valentin).

action potential. This event is manifested on the surface electro-cardiogram as a proiongation of the QT interval (Vandenberg, Walker, & Campbell, 2001). While QT interval prolongation is not pract-rhythmic per se, under certain conditions and in a small percentage of patients it has been associated with TdP, which either spontaneously terminates or degenerates into ventricular fibrillation and may therefore lead to sudden death (Pugsley, Authier, & Curtis, 2008; en. 2008).

Roden, 2008). To address this serious head (vigger, human, i address Conference on Harmonization of Technical Be guinements for Rogitza-tion of the S78 guideline. This guideline recommends an in vitro assessment of NBRG channel inhibition in conjunction with in vitro assessment of codeyed repolatization (OZ produced and the second casessment of codeyed expolatization (OZ produced and the second per to conduce of delived at the second and the second and the transformed of the second and the second and the second per to conduce of delived at the second and the second and the transformed at the second and the second and the second and the transformed at the second and the second and

Register or Login: Password:	SIGN IN 📃 Auto-Login [Re	minder]
Search This Periodical	Y for	GO
Advanced Search - MEDLINE - My Recei	t Searches - My Saved Searches - Se	arch Tips

### results list

I	ABSTRACT
	FULL TEXT
	FULL-TEXT PDF (603 KB)
	CITATION ALERT
	CITED BY
	RELATED ARTICLES
	EXPORT CITATION
	EMAIL TO A COLLEAGUE
	RIGHTS/PERMISSIONS
	畿 IOVALOAD IMAGES
	NEED REPRINTS?
	BOOKMARK ARTICLE
	FULL TEXT FLSEWHERE

### <sup>a</sup> GlaxoSmithKline Safety Assessment, Research Triangle Park, NC Journal of Pharmacological and Toxicological Methods 61 (2010) 1-2 Contents lists available at ScienceDirect merican Heart Iournal JOURNAL HOME Journal of Pharmacological and Toxicological Methods CURRENT ISSUE journal homepage: www.elsevier.com/locate/jpharmtos BROWSE ALL ISSUES ARTICLES IN PRESS Original article A call for more integrated cardiovascular safety assessment ONLINE EXCLUSIVE S.D. Pettit <sup>a,\*</sup>, B. Berridge <sup>b</sup>, R.D. Sarazan <sup>c</sup> ONLINE LETTERS \* IISI Health and Environmental Sciences Institute, 1156 15th St, NW, Washington DC, USA <sup>10</sup> Glassifichildine Safety Assessment, 5 Moore: Drive, Research Triangle Park, NC 27709, USA <sup>6</sup> Gavance Laboratories, Inc., 3301 Kimman Biol, Mitdian, WI 53704, USA vious Aims and Scope Editorial Board ARTICLE INFO ABSTRACT Cardiovascular safety concerns are a significant cause of attrition in the development of new drugs (Lasse Anticle history. Milicie Austory: Received 2 July 2009 Accepted 13 August 20 Cardioxecular subty morema are a agentical case of alterion in the development of new drug (Laser et al., 2003), this activation has applied on public health inplications and also constructives to the sing const of all cases. The second chick a predictor/mounter of cardioxecular tria as wells as more inegrated and predictive development strategy could characterized symaptic the development of also and detrice medicates for public triats and trategy could characterized symaptic the development of also and detrice medicates for public to the distribution of t Pricing Information

Sciences Institute (ILSI HESI) in June 2009 in Washington, D.C. This highly interactive scientific forum

Register or Login:

Search This Periodical

Password:

✓ for

dvanced Search - MEDLINE - My Recent Searches - My Saved Searches - Search Tips

SIGN IN Auto-Login [Reminder]

✓ previous 7 of 34 next >

CITATION ALERT

RELATED ARTICLES

EMAIL TO A COLLEAGUE

RIGHTS/PERMISSIONS

EXPORT CITATION

NEED REPRINTS?

BOOKMARK ARTICLE

FULL TEXT FLSEWHERE

FULL-TEXT PDF (156 KB)

▶ ABSTRACT

CITED BY

EUL TEXT

GO

**Recent Pubs** 

A translational approach to detecting drug-induced cardiac injury with cardiac troponins: Consensus and

William J. Reagan, DVM, PhD<sup>a</sup>, Steven E. Lipshultz, MD<sup>b</sup>, Fred S. Apple, PhD<sup>1</sup>, Malcolm J. York, MPhil

recommendations from the Cardiac Troponins Biomarker Working Group of the Health and Environmental Sciences

Brian R. Berridge, DVM, PhD# DV., Svril Petiti, MS<sup>b</sup>, Dana B. Walker, DVM, PhD<sup>a</sup>, Alan S. Jaffe, MD<sup>d</sup>, Albert E. Schultze, DVM, PhD<sup>a</sup>, Eugene Herman, PhD<sup>f</sup>,

Cardiac troponins (cTns) are established biomarkers of ischemic heart disease in humans. However, their value as biomarkers of cardiac injury from causes

other than ischemic heart disease is now being explored, particularly in drug development. In a workshop sponsored by the Cardiac Troponin Biomarker Working

Group of the Health and Environmental Sciences Institute, preclinical, clinical, and regulatory scientists discussed the application of cTns in their respective environments, issues in translating the preclinical application of cTn to clinical studies, and gaps in our understanding of cTn biology and pathobiology. Evidence

indicates that cTns are sensitive and specific biomarkers of cardiac injury from varying causes in both animals and humans. Accordingly, monitoring cTns car

help ensure patient safety during the clinical evaluation of new drugs. In addition, preclinical characterization of cardiac risk and cTns as biomarkers of that risk can guide relevant clinical application and interpretation. We summarize here the outcomes of the workshop which included consensus statements,

recommendations for further research, and a proposal for a cross-disciplinary group of clinical, regulatory, and drug development scientists to collaborate in such

American Heart Iourna

Volume 158, Issue 1, Pages 21-29 (July 2009)

Received 23 April 2009; accepted 23 April 2009

b ILSI Health and Environmental Scie

C Bristol-Myers Squibb, East Syracu

e Pathology Department, Eli Lilly and

<sup>f</sup> FDA Center for Drug Evaluation an

<sup>g</sup> Drug Safety Evaluation, Pfizer Inc. h Department of Pediatrics, Universi

Hennepin County Medical Center, N

GlaxoSmithKline Safety Assessme

Reprint requests: Brian R. Berrid

© 2009 Mosby, Inc. All rights reserv

PII: \$0002-8703(09)00297-X

doi:10.1016/j.ahj.2009.04.020

Copyright © 2010 Elsevier, Inc. All rights reserved | Privacy Policy | Terr The content on this site is intended for health professionals.

<sup>1</sup> Mayo Clinic, Rochester, MN

Institute

research

JOURNAL HOME

CURRENT ISSUE

BROWSE ALL ISSUES

ARTICLES IN PRESS

ONLINE EXCLUSIVE

ONLINE LETTERS

SEARCH THIS JOURNAL

JOURNAL INFORMATION

Permission to Reuse

Info for Advertisers

Contact Information

Pricing Information

AUTHOR INFORMATION

SUBSCRIBE TO JOURNAL CAREER OPPORTUNITIES RSS

ONLINE SUBMISSION

More periodicals

FIND A PORTAL

FIND A PERIODICAL

GO TO PRODUCT CATALOG

Aims and Scope

Editorial Board

CONFERENCE HIGHLIGHT

acouses montime (u.z. res.y.) mpre. 2005 m Washington, DL. This highly interactive scientific formu-provided a uning-opportunity for experts with diverse calaboxacular-related expertise to collectively discuss items, challenges, and opportunities to improve the overall pharmacentical cardiovascular safety assessment paradigm. This article identifies the major points of consensus and recommendations stemning from this workshop. © 2009 Elsevier Inc. All rights reserved

Cardiovascular safety concerns are a significant cause of attrition in the development of new drugs (Lasser et al., 2002). These risks are present in a variety of ways from acute changes in electrophysiology or hemodynamics to longer term changes in cardiac contractility or cardiovascular structure. Despite the relative frequency with which cardiovascular effects are observed during the drug development cardiovascular effects are observed during the drug development process, current approaches in the pharmacetalia industry and the regulatory (e.g. EH S7a and b) guidances that influence those practices are predominately focused on QT protogation and autre cardiovascular effects. Also, there is rising concern about those untoward and unexpected cardiovascular effects: that emerge in

high-risk patient populations not modeled in nonclinical studies. The public health implications of cardiovascular safety-related attrition are significant but this attrition also contributes to the rising cost of developing new drugs. Late stage (clinical) terminations or withdrawals put patient populations at risk. Inappropriate terminations during nonclinical phases of development for unproven risks may essarily limit the future of a compound that could benefit a target

Abbeviations: ILSI HES, International Life Sciences Institute Health and Environ-mental Sciences Institute; ICH, International Conference on Hamonization; QT, duration office (IT Internat) of the electrocatiguram. \* Corresponding author: Health and Environmental Sciences Institute, 1156 15th

patient population. In either scenario, a better understanding of the inter-relationship between nonclinical and clinical predictors/measures of cardiovascular risk as well as a more integrated and predictive development strategy could dramatically augment the development of safe and effective medicines for patients in need.

In response to this need, a consortium of industrial, academic, and government scientists designed and executed a three day 'think tank' under the auspices of the non-profit ILSI Health and Environmental Sciences Institute (ILSI HESI). The session was held from June 2 to 4, 2009, in Washington, D.C. This highly interactive scientific forum provided a unique opportunity for experts with diverse cardiovascular-related expensise to collectively discuss issues, challenges, and opportunilies to improve the overall pharmaceutical cardiovascular safety assessment paradigm. The think tark' drew approximately sixty scientists from the U.S., Europe, and Japan and included regulators, clinicians, academic research scientists, and industrial researchers (both dinical and nonclinical). The meeting agenda and are as of focus were specifically intended to integrate approaches to both cardiovascular structure and function as they relate to clinical and nonclinical drug development. The group discussed strategic gaps and formulated ideas for collaborative efforts to address those gaps Specific sessions explored: evaluation of acute changes in cardiac hemodynamics and inotropy, analytical sensitivity of contemporary

SEARCH THIS JOURNAL CONFERENCE HIGHLIGHTS JOURNAL INFORMATION · Permission to Reuse · Info for Advertisers Contact Information AUTHOR INFORMATION ONLINE SUBMISSION

Received 4 June 2009: accepted 4 June 2009, published online 24 July 2009. In October 2008, in a public forum organized by the Cardiac Safety Research Consortium and the Health and Environmental Sciences Institute, leaders from government, the pharmaceutical industry, and academia convened in Bethesda, MD, to discuss current challenges in evaluation of short- and long-term

Volume 158, Issue 3, Pages 317-326 (September 2009)

cardiovascular safety during drug development. The current paradigm for premarket evaluation of cardiac safety begins with preclinical animal modeling and progresses to clinical biomarker or biosignature assays. Preclinical evaluations have clear limitations but provide an important opportunity to identify safety hazards before administration of potential new drugs to human subjects. Discussants highlighted the need to identify, develop, and validate serum and electrocardiogram biomarkers indicative of early drug-induced myocardial toxicity and proarrhythmia. Specifically, experts identified a need to build consensus regarding the use and interpretation of troponin assays in preclinical evaluation of myocardial toxicity. With respect to proarrhythmia, the panel emphasized a need for better qualitative and quantitative biomarkers for arrhythmogenicity, including more streamlined human thorough QT study designs and a universal definition of the end of the T wave. Toward many of these ends, large shared data repositories and a more seamless integration of preclinical and clinical testing could facilitate the development of novel approaches to both cardiac safety biosignatures. In addition, more thorough and efficient early clinical studies could enable better estimates of cardiovascular risk and better inform phase II and phase III trial design. Participants also emphasized the importance of establishing formal guidelines for data standards and transparency in postmarketing surveillance. Priority pursuit of these consensus-based directions should facilitate both safer drugs and accelerated access to new drugs, as concomitant public health benefits.

Current challenges in the evaluation of cardiac safety during drug development: Translational medicine meets the Critica

odicals:	
ERIODICAL	
DRTAL	<sup>8</sup> Duke Clinical Research Institute & Duke University Medical Center, Durham, NC
	Department of Medicine, Jefferson Medical College, Philadelphia, PA
RODUCT CATALOG	<sup>C</sup> GlaxoSmithKline, Research Triangle Park, NC
	₫ GlaxoSmithKline, Collegeville, PA
	€ ILSI Health and Environmental Sciences Institute, Washington, DC
	<sup>1</sup> Division of Cardiovascular and Renal Products, CDER, FDA, Silver Spring, MD
	<sup>g</sup> AstraZeneca, Cheshire, United Kingdom
	h Amgen, Inc., Thousand Oaks, CA

Reprint requests: Mitchell W. Krucoff, MD, FACC, FCCP, eECG Core Laboratory, Duke Clinical Research Institute, 508 Fulton Street, Durham, NC 27705

Plt S0002-8703(09)00449-9

doi:10.1016/j.ahj.2009.06.007

© 2009 Mosby, Inc. All rights reserved

for the CSRC/HESI Writing GroupJonathan P. Piccini, MD, MHS<sup>8</sup>, David J. Whellan, MD, MHS<sup>8</sup>, Brian R. Berridge, DVM, PhD<sup>a</sup>, John K. Finkle, MD<sup>d</sup>, Svril D. Pettil, MEM<sup>a</sup>, Norman Stockbridge, MD, PhD<sup>f</sup>, Jean-Pierre Valentin, PhD<sup>a</sup>, Hugo M, Vargas, PhD<sup>b</sup>, Mitchell W, Krucoff, MD

Path Initiative

SUBSCRIBE TO JOURNAL

RSS

More peri FIND A PE

FIND A PO

GO TO PE

CAREER OPPORTUNITIES

# **Moving Forward**

### **Enriched Portfolio**


- Strong research, publication, and 'think tank' platform established within Committee.
- Expertise and interests shared across project teams leading to focus on 'integrated' approaches to cardiovascular assessment in project portfolio.
- HESI Cardiac Technical Committee gaining recognition as a resource

Opportunity today to learn more and we invite you to participate with the program in the future!

# Functional Cardiovascular Safety Working Group

Fall 2009 - Present


# The Cardiovascular System



**Figure 13–5.** The events of the cardiac cycle, showing changes in left atrial pressure, left ventricular pressure, aortic pressure, ventricular volume, the electrocardiogram, and the phonocardiogram.


### **Drug Safety Assessment: 1997-Present**





### Why The Obsession with ECGs?

- Terfenadine (Seldane<sup>®</sup>)
- Astemizole (Hismanal<sup>®</sup>)
- Cisapride (Propulsid<sup>®</sup>)
- Sertindole (Serlect<sup>®</sup>)
- Vardenafil (Levitra<sup>®</sup>)
- Ziprasidone (Geodon<sup>®</sup>)



This started a frenzy of regulatory activity in the 1990s, focused almost entirely on drug-induced QT interval prolongation! CURRENT PRACTICE IN STRUCTURAL AND FUNCTIONAL ASSESSMENT OF CARDIOVASCULAR TOXICITY: ISSUES AND OPPORTUNITIES

> S. Pettit, B. Berridge, D. Sarazan Co-Chairs



E

н

JUNE 2-4, 2009 THE MADISON HOTEL WASHINGTON, DC 20005 Journal of Pharmacological and Toxicological Methods 61 (2010) 1-2





Journal of Pharmacological and Toxicological Methods



journal homepage: www.elsevier.com/locate/jpharmtox

### Original article

### A call for more integrated cardiovascular safety assessment

### S.D. Pettit <sup>a,\*</sup>, B. Berridge <sup>b</sup>, R.D. Sarazan <sup>c</sup>

<sup>a</sup> ILSI Health and Environmental Sciences Institute, 1156 15th 5t, NW, Washington DC, USA <sup>b</sup> Glavaomithkline Safety Assessment, 5 Moore Drive, Research Triangle Park, NC 27709, USA <sup>c</sup> Covance Laboratories, IA, 301 Kinsmen Bird, Madison, WI 53704, USA

### ARTICLE INFO

### ABSTRACT

Article history: Received 2 July 2009 Accepted 13 August 2009

Keywords: Cardiovascular safety Drug development Consortia Cardiovascular safety concerns are a significant cause of attrition in the development of new drugs (Lasser et al., 2002). This attrition has significant public health implications and also contributes to the rising cost of developing new drugs. However, a better understanding of the inter-relationship between nonclinical and clinical predictors/measures of cardiovascular risk as well as a more integrated and predictive development strategy could dramatically augment the development of safe and effective medicines for patients in need. In response to this need, a consortium of industrial, academic, and government scientistis designed and executed a three day think tank' under the auspices of the non-profit IISI Health and Environmental Sciences Institute (IISI HESI) in June 2009 in Washington, D.C. This highly interactive scientific forum provided a unique opportunity for experts with diverse cardiovascular-related expertise to collectively assessment paradigm. This article identifies the major points of consensus and recommendations stemming from this workshop.

© 2009 Elsevier Inc. All rights reserved.

Cardiovascular safety concerns are a significant cause of attrition in the development of new drugs (lasser et al. 2002). These risks are present in a variety of ways from acute changes in electrophysiology or hemodynamics to longer term changes in cardiac contractility or cardiovascular effects are observed during the drug development process, current approaches in the pharmaceutical industry and the regulatory (e.g., ICH S7a and b) guidances that influence those practices are predominately focused on QT prolongation and acute cardiovascular effects. Also, there is rising concern about those untoward and unexpected cardiovascular effects that emerge in high-risk patient populations not modeled in nonclinical studies.

The public health implications of cardiovascular safety-related attrition are significant but this attrition also contributes to the rising cost of developing new drugs. Late stage (clinical) terminations or withdrawals put patient populations at risk. Inappropriate terminations during nonclinical phases of development for unproven risks may unnecessanly limit the future of a compound that could benefit a target patient population. In either scenario, a better understanding of the inter-relationship between nonclinical and clinical predictors/measures of cardiovascular risk as well as a more integrated and predictive development strategy could dramatically augment the development of safe and effective medicines for patients in need.

In response to this need, a consortium of industrial, academic, and government scientists designed and executed a three day 'think tank' under the auspices of the non-profit ILSI Health and Environmental Sciences Institute (ILSI HESI). The session was held from June 2 to 4, 2009, in Washington, D.C. This highly interactive scientific forum provided a unique opportunity for experts with diverse cardiovascular-related expertise to collectively discuss issues, challenges, and opportunities to improve the overall pharmaceutical cardiovascular safety assessment paradigm. The 'think tank' drew approximately sixty scientists from the U.S., Europe, and Japan and included regulators, clinicians, academic research scientists, and industrial researchers (both clinical and nonclinical). The meeting agenda and areas of focus were specifically intended to integrate approaches to both cardiovascular structure and function as they relate to clinical and nonclinical drug development. The group discussed strategic gaps and formulated ideas for collaborative efforts to address those gaps. Specific sessions explored: evaluation of acute changes in cardiac hemodynamics and inotropy, analytical sensitivity of contemporary study paradigms, current understanding of structural cardiotoxicity, the impact of therapeutic drug class for cardiovascular risk tolerance, unique challenges of assessing cardiovascular risk with large

Abbreviations: ILSI HESI, International Life Sciences Institute Health and Environmental Sciences Institute; ICH, International Conference on Harmonization; QT, duration of the OT interval of the electrocardiogram.

Corresponding author. Health and Environmental Sciences Institute, 1156 15th Street, NW, 2nd floor, Washington, DC 20005, USA. Tel.: +1202 659 3306; fax: +1202 659 3817.

E-mail addresses: spetfit@isi.org (S.D. Pettit), brian.x.berridge@gsk.com (B. Berridge), Dusty.Sarazan@covance.com (R.D. Sarazan).

<sup>1056-8719/\$ -</sup> see front matter © 2009 Elsevier Inc, All rights reserved, doi:10.1016/j.v.ascn.2009.08.001

### Toward an Integrated Approach to Cardiovascular Safety Assessment

D. Sarazan, S. Pettit, B. Berridge

Presented at the SPS 9<sup>th</sup> Annual Meeting Strasbourg, France 21 – 24 September 2009

Poster and invited platform presentation

# What has happened since?

- Functional CV Subteam has been meeting monthly via teleconference;
- Outline for paper on gaps, opportunities, recommended approaches developed <u>collectively</u> by work group and discussed in detail on series of teleconferences;
- Small writing team preparing initial draft document (D. Sarazan, J. Koerner, S. Mittelstadt, B. Guth, J. Zhang) based on outline developed by full work group;
- Draft of manuscript to be shared with full work group in June 2010 for input;
- Manuscript anticipated to be complete in August/September 2010.

## Manuscript Outline

### I. Introduction II. Hemodynamics

Background Current Status of Approaches Mechanistic Interpretation/Biology Recent Advances In Technology Recommendations for Further Actions

### III. Cardiac Contractility (Inotropy)

Background

Current Status of Approaches Mechanistic Interpretation/Biology Recent Advances In Technology Recommendations for Further Actions

### IV. Functional CV Assessment in Repeat Dose Toxicology Studies

Background Current Status of Approaches Mechanistic Interpretation/Biology Recent Advances In Technology Recommendations for Further Actions

(continued)

# Manuscript Outline Cont'd

### V. Assay Sensitivity

- Background
- Definition of sensitivity
  - Statistical Power
  - Positive Control
- Types of Study Designs
- Recommendations

VI. Conclusions/Recommendations VII. References

# What happens after manuscript?

- Team will prioritize recommendations for next steps;
- Possible data sharing or experimental project proposed to assess the power of nonclinical functional studies to predict clinical functional outcomes;
- More specific direction to be determined following HESI Committee meeting June 2-3, 2010.



## Thank You!

## FOR BACKUP OR DISCUSSION

0



## **Discussion Questions**

What's the scope of the problem?

•What are the key CVS safety liabilities in Drug Discovery, Drug Development and Clinical Practice?

- How big is the problem? •How significant are CVS safety liabilities in affecting drug development, registration, clinical practice and marketability?
- What do we know about it?

•Do we understand the mechanisms of CVS toxicities? If not...

- What can we do about it?
  - •How effective are current strategies and BMs of CVS toxicities?
  - •What are the gaps in our knowledge concerning CVS toxicities?
  - •What is required to fill those gaps? Preclinically / clinically?
  - •Where should effort be focused on in the next 5 years?
- What is the role for collaboration?
  - How have/can collaborative programs influence the development of new CVS science?
  - Are these programs reaching their potential? If not how can these approaches be improved?